Citations

Clear

1011 citation(s) found for "Barry, WT".

Kidney Disease, Intensive Hypertension Treatment, and Risk for Dementia and Mild Cognitive Impairment: The Systolic Blood Pressure Intervention Trial
Tamura, Manjula Kurella , Gaussoin, Sarah A. , Chelune, Gordon J. , Gure, Tanya R. , Haley, William E. , Killeen, Anthony A. , Oparil, Suzanne , Rapp, Stephen R. , Supiano, Mark A. , Williamson, Jeff D. , Kurella Tamura, Manjula , Haley, William E , Killeen, Anthony A , Supiano, Mark A , Pajewski, Nicholas M. , Freedman, Barry I. , Rifkin, Dena E. , Weiner, Daniel E.

Mayo Clinic

Journal of the American Society of Nephrology | June 26, 2020 | Volume: 31 | Issue: 9 | Pages: 2122-2132

10.1681/asn.2020010038 | PMID 32591439 Get It

Significance Statement Intensive treatment of hypertension is beneficial for cardiovascular disease and cognitive function, but at the short-term expense of reduced kidney function. In a randomized trial of intensive versus standard systolic BP lowering, the authors found an association between a large decline in eGFR and increased incidence of probable dementia and mild cognitive impairment, but no link between urinary albumin-to-creatinine ratio and occurrence of dementia or mild cognitive impairment. Decline in eGFR occurred more frequently in the intensive treatment group, but did not modify the beneficial effect of intensive treatment on cognitive function. Among hypertensive adults, declining eGFR may be a marker for those at higher risk for dementia or mild cognitive impairment, independent of the intensity of hypertension treatment. Background Intensively treating hypertension may benefit cardiovascular disease and cognitive function, but at the short-term expense of reduced kidney function. Methods We investigated markers of kidney function and the effect of intensive hypertension treatment on incidence of dementia and mild cognitive impairment (MCI) in 9361 participants in the randomized Systolic Blood Pressure Intervention Trial, which compared intensive versus standard systolic BP lowering (targeting <120 mm Hg versus <140 mm Hg, respectively). We categorized participants according to baseline and longitudinal changes in eGFR and urinary albumin-to-creatinine ratio. Primary outcomes were occurrence of adjudicated probable dementia and MCI. Results Among 8563 participants who completed at least one cognitive assessment during follow-up (median 5.1 years), probable dementia occurred in 325 (3.8%) and MCI in 640 (7.6%) participants. In multivariable adjusted analyses, there was no significant association between baseline eGFR <60 ml/min per 1.73 m 2 and risk for dementia or MCI. In time-varying analyses, eGFR decline ≥30% was associated with a higher risk for probable dementia. Incident eGFR <60 ml/min per 1.73 m 2 was associated with a higher risk for MCI and a composite of dementia or MCI. Although these kidney events occurred more frequently in the intensive treatment group, there was no evidence that they modified or attenuated the effect of intensive treatment on dementia and MCI incidence. Baseline and incident urinary ACR ≥30 mg/g were not associated with probable dementia or MCI, nor did the urinary ACR modify the effect of intensive treatment on cognitive outcomes. Conclusions Among hypertensive adults, declining kidney function measured by eGFR is associated with increased risk for probable dementia and MCI, independent of the intensity of hypertension treatment.
Prognostic Implications of Inferior Vena Cava Haemodynamics in Ambulatory Patients with Tetralogy of Fallot
Egbe, Alexander C. , Connolly, Heidi M. , Miranda, William R. , Scott, Christopher G. , Borlaug, Barry A.

Mayo Clinic

ESC Heart Failure | June 26, 2020 | Volume: 7 | Issue: 5 | Pages: 2589-2596

10.1002/ehf2.12836 | PMID 32588556 Get It

Abstract Aims Right atrial pressure (RAP) provides a composite measure of right ventricular diastolic dysfunction, right atrial compliance, and volume status, and these three variables are typically abnormal in adults with repaired tetralogy of Fallot (TOF). RAP is a well-established prognostic metric in patients with pulmonary hypertension, and recent data suggest that RAP is associated with clinical outcomes in TOF. The purpose of this study was to determine the role of inferior vena cava (IVC) haemodynamics (size and collapsibility) for the assessment of RAP and its potential application for risk stratification and prognostication in the TOF population. Methods and results Adult TOF patients with echocardiographic assessment of IVC haemodynamics were divided into patients with (derivation cohort, n = 256) and without (validation cohort, n = 492) cardiac catheterization data. We assessed the correlation between IVC haemodynamics, RAP, and disease severity indices [arrhythmias, peak oxygen consumption (VO2), and heart failure hospitalization] in derivation cohort and compared it with the correlations in the validation cohort. IVC haemodynamics correlated with RAP (r = 0.52, P &lt; 0.001), with disease severity indices {atrial arrhythmias [area under the curve (AUC) 0.81], ventricular arrhythmias [AUC 0.67], heart failure hospitalizations [AUC 0.78], and peak VO2 [r = 0.53]}, and with transplant-free survival in the derivation cohort. Similar correlations between IVC haemodynamics, disease severity indices, and transplant-free survival were also observed in the validation cohort. Conclusions These findings suggest that IVC haemodynamics can potentially be used for risk stratification and prognostication in TOF patients and can complement the current risk models that are based predominately on right ventricular volumes and systolic function.
Getting the “Right” Perspective on Angiotensin Receptor–Neprilysin Inhibition in Heart Failure
Verbrugge, Frederik H. , Borlaug, Barry A. , Borlaug, Barry A , Verbrugge, Frederik H

Mayo Clinic

Journal of the American Heart Association | June 18, 2020 | Volume: 9 | Issue: 13 | Pages: No page available

10.1161/jaha.120.017292 | PMID 32552147 Get It

The Prognostic Value of Lactate in Cardiac Intensive Care Unit Patients With Cardiac Arrest and Shock
Burstein, Barry , Vallabhajosyula, Saraschandra , Ternus, Bradley , Barsness, Gregory W. , Vallabhajosyula, Saraschandra , Kashani, Kianoush , Jentzer, Jacob C.

Mayo Clinic

Shock | June 3, 2020 | Volume: 55 | Issue: 5 | Pages: 613-619

10.1097/shk.0000000000001582 | PMID 32496423 Get It

ABSTRACT Background: Lactate is a prognostic marker in critically ill patients, although currently available illness severity scores do not include lactate as a predictive parameter. We sought to describe the association between lactate and hospital mortality in patients admitted to the cardiac intensive care unit (CICU) with cardiac arrest (CA) and shock. Methods: Retrospective observational analysis of Mayo Clinic CICU patients admitted from 2007 to 2018 with measured lactate on admission, including patients with and without CA or shock. We examined hospital mortality as a function of admission lactate in patients. Multivariable logistic regression was used to determine predictors of hospital mortality. Results: We included 3,042 patients with a median age of 70 years (IQR 60–80), including 41% females, 26% with CA, and 39% with shock. The median APACHE-IV predicted mortality was 24% (IQR 11–51%), and the median admission lactate was 1.8 mmol/L (IQR 1.1–3.0). Hospital mortality occurred in 23% of patients and rose progressively with higher admission lactate, including in patients with and without CA or shock. After multivariable adjustment for clinical characteristics, therapies, and illness severity, a higher lactate remained associated with increased hospital mortality (adjusted OR 1.13 per mmol/L, 95% CI 1.06–1.20, P < 0.001). Conclusions: Admission lactate levels are strongly associated with increased hospital mortality among CICU patients, including those with and without CA or shock. The prognostic value of lactate levels is independent of established ICU prognostic scores and dependent on admission diagnosis, which may help inform clinicians caring for CICU patients.
New Insights into the Role of Left Atrial Function During Exercise in Heart Failure
Reddy, Yogesh N.V. , Nishimura, Rick , Borlaug, Barry A.

Mayo Clinic

European Journal of Heart Failure | May 27, 2020 | Volume: 22 | Issue: 7 | Pages: 1199-1201

10.1002/ejhf.1903 | PMID 32459014 Get It

Scientific Societies Fostering Inclusive Scientific Environments through Travel Awards: Current Practices and Recommendations
Vega, Leticia R. , Primus, Clara, Etson, Candice M. , Guillory, Ashley N. , Edwards, Ashanti, Flores, Sonia C., Fry, Catherine, Ingram, Susan , Lawson, Mark A. , McGee, Richard , Paxson, Stephanie, Phelan, Laura, Suggs, Kirsta, Vuong, Elizabeth, Hammonds-Odie, Latanya , Leibowitz, Michael J. , Zavala, MariaElena, Luján, J. Luis , Ramirez-Alvarado, Marina, Segarra, Verónica A. , Ramı́rez-Alvarado, Marina

Mayo Clinic

CBE—Life Sciences Education | May 26, 2020 | Volume: 19 | Issue: 2 | Pages: es3

10.1187/cbe.19-11-0262 | PMID 32453676 Get It

This essay compares the approaches that scientific societies in the ACCESS meta-organization use to implement and assess travel award programs for URM trainees and presents a set of recommendations, including both short- and long-term outcomes assessment in populations of interest and specialized programmatic activities coupled to travel award programs.
Redistribution of cardiac output during exercise by functional mitral regurgitation in heart failure: compensatory O2 peripheral uptake to delivery failure
Generati, Greta, Alfonzetti, Eleonora, Sugimoto, Tadafumi , Borlaug, Barry, Guazzi, Marco , Borlaug, Barry A. , Castelvecchio, Serenella , Menicanti, Lorenzo , Bandera, Francesco

Mayo Clinic

American Journal of Physiology-Heart and Circulatory Physiology | May 22, 2020 | Volume: 319 | Issue: 1 | Pages: H100-H108

10.1152/ajpheart.00125.2020 | PMID 32442022 Get It

This is an analysis involving 134 heart failure patients with reduced ejection fraction versus 80 controls investigated during functional evaluation with gas exchange and hemodynamic, addressing the severe mitral regurgitation phenotype and testing the hypothesis that the backward cardiac output redistribution to the lung during exercise impairs delivery and overexpresses peripheral extraction. This information is new and has important implications in the management of heart failure.
Characterization of the Inflammatory-Metabolic Phenotype of Heart Failure with a Preserved Ejection Fraction: A Hypothesis to Explain Influence of Sex on the Evolution and Potential Treatment of the Disease
Lund, Lars H. , Packer, Milton , Lam, Carolyn S.P. , Maurer, Mathew S., Borlaug, Barry A.

Mayo Clinic

European Journal of Heart Failure | May 22, 2020 | Volume: 22 | Issue: 9 | Pages: 1551-1567

10.1002/ejhf.1902 | PMID 32441863 Get It

Abstract Accumulating evidence points to the existence of an inflammatory-metabolic phenotype of heart failure with a preserved ejection fraction (HFpEF), which is characterized by biomarkers of inflammation, an expanded epicardial adipose tissue mass, microvascular endothelial dysfunction, normal-to-mildly increased left ventricular volumes and systolic blood pressures, and possibly, altered activity of adipocyte-associated inflammatory mediators. A broad range of adipogenic metabolic and systemic inflammatory disorders – e.g. obesity, diabetes and metabolic syndrome as well as rheumatoid arthritis and psoriasis – can cause this phenotype, independent of the presence of large vessel coronary artery disease. Interestingly, when compared with men, women are both at greater risk of and may suffer greater cardiac consequences from these systemic inflammatory and metabolic disorders. Women show disproportionate increases in left ventricular filling pressures following increases in central blood volume and have greater arterial stiffness than men. Additionally, they are particularly predisposed to epicardial and intramyocardial fat expansion and imbalances in adipocyte-associated proinflammatory mediators. The hormonal interrelationships seen in inflammatory-metabolic phenotype may explain why mineralocorticoid receptor antagonists and neprilysin inhibitors may be more effective in women than in men with HFpEF. Recognition of the inflammatory-metabolic phenotype may improve an understanding of the pathogenesis of HFpEF and enhance the ability to design clinical trials of interventions in this heterogeneous syndrome.